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The cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6) is an enzyme that is 
predominantly involved in the metabolism of tamoxifen. Genetic polymorphisms of the 
CYP2D6 gene may contribute to inter-individual variability in tamoxifen metabolism, which 
leads to the differences in clinical response to tamoxifen among breast cancer patients. In 
Malaysia, the knowledge on CYP2D6 genetic polymorphisms as well as metabolizer status in 
Malaysian breast cancer patients remains unknown. Hence, this study aimed to 
comprehensively identify CYP2D6 genetic polymorphisms among 80 Malaysian breast 
cancer patients. The genetic polymorphisms of all the 9 exons of CYP2D6 gene were 
identified using high-resolution melting analysis and confirmed by DNA sequencing. Seven 
CYP2D6 alleles consisting of CYP2D6*1, CYP2D6*2, CYP2D6*4, CYP2D6*10, 
CYP2D6*39, CYP2D6*49, and CYP2D6*75 were identified in this study. Among these 
alleles, CYP2D6*10 is the most common allele in both Malaysian Malay (54.8%) and 
Chinese (71.4%) breast cancer patients, whereas CYP2D6*4 in Malaysian Indian (28.6%) 
breast cancer patients. In relation to CYP2D6 genotype, CYP2D6*10/*10 is more frequently 
observed in both Malaysian Malay (28.9%) and Chinese (57.1%) breast cancer patients, 
whereas CYP2D6*4/*10 is more frequently observed in Malaysian Indian (42.8%) breast 
cancer patients. In terms of CYP2D6 phenotype, 61.5% of Malaysian Malay breast cancer 
patients are predicted as extensive metabolizers in which they are most likely to respond well 
to tamoxifen therapy. However, 57.1% of Chinese as well as Indian breast cancer patients are 
predicted as intermediate metabolizers and they are less likely to gain optimal benefit from 
the tamoxifen therapy. This is the first report of CYP2D6 genetic polymorphisms and 
phenotypes in Malaysian breast cancer patients for different ethnicities. These data may aid 
clinicians in selecting an optimal drug therapy for Malaysian breast cancer patients, hence 
improve the clinical outcome of the patients.  
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